Aristides Capital’s Vir Biotechnology VIR Stock Holding History

Aristides Capital’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-23,743	Closed	-$239K	–	366
2023 Q4	$239K	Buy	+23,743	New	+$217K	0.09%	179

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Aristides Capital's VIR Position: Q1 2024 in Review

Aristides Capital sold out of Vir Biotechnology (VIR) in Q1 2024, closing a stake of 23,743 shares — an estimated $239K sold.

Aristides Capital first reported a position in VIR in Q4 2023 and held it in 1 quarter. The position peaked at $239K in Q4 2023. 209 funds tracked by Wall St. Rank hold VIR as of Q1 2024.

Aristides Capital reported no remaining Vir Biotechnology position as of Q1 2024 after selling out during the quarter.
Aristides Capital sold 23,743 Vir Biotechnology shares in Q1 2024, an estimated $239K.
Aristides Capital first reported a position in Vir Biotechnology in Q4 2023 and held it in 1 quarter.
Aristides Capital's Vir Biotechnology position peaked at $239K in Q4 2023.
209 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2024.

Based on Aristides Capital's 13F filing for Q1 2024, filed 15 May 2024.